US FDA Vaccine Committee Meeting Postponed

The previously scheduled U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to determine which strains of influenza should be used in the 2025-2026 seasonal influenza vaccines is no longer listed on the FDA website.

As of February 27, 2025, Inside Medicine reported that a current VRBPAC member confirmed the schedule change.

The VRBPAC meets twice yearly to evaluate the effectiveness of approved flu shots and determine if the influenza strains have changed between the Southern and Northern hemispheres. Once a determination is rendered, the FDA coordinates with vaccine manufacturers and the World Health Organization.

The FDA uses committees and panels to obtain independent expert advice on scientific, technical, and policy matters.